Details for New Drug Application (NDA): 218933
✉ Email this page to a colleague
NDA 218933 describes AVERI, which is a drug marketed by Avion Pharms and is included in one NDA. Additional details are available on the AVERI profile page.
The generic ingredient in AVERI is desogestrel; ethinyl estradiol. There is one drug master file entry for this compound. Fifteen suppliers are listed for this compound. Additional details are available on the desogestrel; ethinyl estradiol profile page.
The generic ingredient in AVERI is desogestrel; ethinyl estradiol. There is one drug master file entry for this compound. Fifteen suppliers are listed for this compound. Additional details are available on the desogestrel; ethinyl estradiol profile page.
Summary for 218933
| Tradename: | AVERI |
| Applicant: | Avion Pharms |
| Ingredient: | desogestrel; ethinyl estradiol |
| Patents: | 0 |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL-21 | Strength | 0.15MG;0.03MG | ||||
| Approval Date: | May 2, 2025 | TE: | RLD: | No | |||||
Profile for product number 002
| Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL-28 | Strength | 0.15MG;0.03MG | ||||
| Approval Date: | May 2, 2025 | TE: | AB | RLD: | No | ||||
Complete Access Available with Subscription
